EE05318B1 - Geelkompositsioon ja kompositsiooni transskrotaalne kasutamine hpogonadismi raviks - Google Patents

Geelkompositsioon ja kompositsiooni transskrotaalne kasutamine hpogonadismi raviks

Info

Publication number
EE05318B1
EE05318B1 EEP200300305A EEP200300305A EE05318B1 EE 05318 B1 EE05318 B1 EE 05318B1 EE P200300305 A EEP200300305 A EE P200300305A EE P200300305 A EEP200300305 A EE P200300305A EE 05318 B1 EE05318 B1 EE 05318B1
Authority
EE
Estonia
Prior art keywords
composition
treatment
transcrotal
pogonadism
gel
Prior art date
Application number
EEP200300305A
Other languages
English (en)
Estonian (et)
Inventor
Schulze Bernd
Nieschlag Eberhard
Original Assignee
Dr. August Wolff Gmbh & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. August Wolff Gmbh & Co. filed Critical Dr. August Wolff Gmbh & Co.
Publication of EE200300305A publication Critical patent/EE200300305A/xx
Publication of EE05318B1 publication Critical patent/EE05318B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Cosmetics (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Dental Preparations (AREA)
  • Steroid Compounds (AREA)
EEP200300305A 2000-12-22 2001-12-20 Geelkompositsioon ja kompositsiooni transskrotaalne kasutamine hpogonadismi raviks EE05318B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10064205 2000-12-22
PCT/EP2001/015123 WO2002051421A2 (fr) 2000-12-22 2001-12-20 Composition de gel et application par voie trans-scrotale d'une composition pour traiter l'hypogonadisme

Publications (2)

Publication Number Publication Date
EE200300305A EE200300305A (et) 2003-12-15
EE05318B1 true EE05318B1 (et) 2010-08-16

Family

ID=7668398

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300305A EE05318B1 (et) 2000-12-22 2001-12-20 Geelkompositsioon ja kompositsiooni transskrotaalne kasutamine hpogonadismi raviks

Country Status (17)

Country Link
US (2) US20040044086A1 (fr)
EP (1) EP1347764B1 (fr)
AT (1) ATE356626T1 (fr)
CA (1) CA2432534C (fr)
CY (1) CY1106595T1 (fr)
CZ (1) CZ20031761A3 (fr)
DE (2) DE50112206D1 (fr)
DK (1) DK1347764T3 (fr)
EE (1) EE05318B1 (fr)
ES (1) ES2283446T3 (fr)
HR (1) HRP20030510A2 (fr)
HU (1) HUP0600234A3 (fr)
PL (1) PL206702B1 (fr)
PT (1) PT1347764E (fr)
SI (1) SI1347764T1 (fr)
SK (1) SK7932003A3 (fr)
WO (1) WO2002051421A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
BRPI0515040B1 (pt) * 2004-09-09 2021-10-13 Besins Healthcare Luxembourg S.A.R.L Géis de testosterona compreendendo propileno glicol como intensificador de penetração
EP1634583A1 (fr) * 2004-09-09 2006-03-15 Laboratoires Besins International Gels de testostérone comprenant du propylèneglycol comme promoteur d'absorption
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
SI1937276T1 (sl) 2005-10-12 2013-04-30 Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road Izboljšani testosteronski gel in postopek uporabe
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860712A (en) * 1973-04-16 1975-01-14 Sterling Drug Inc Composition and method for treatment of acne or seborrhea
CA1165240A (fr) * 1980-07-09 1984-04-10 The Procter & Gamble Company Composes pharmaceutiques a usage topique
CA1249968A (fr) * 1984-04-05 1989-02-14 Kazuo Kigasawa Base pour baume
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
DK3994A (da) * 1994-01-10 1995-07-11 Frank Nielsen CDopbevaringssystem hvor CDcoverne monteres på en skinne
EP0952833A1 (fr) * 1996-05-02 1999-11-03 Azupharma GmbH Application topique d'androgene par voie penienne pour le traitement de la dyserection
EP0954260A1 (fr) * 1996-05-22 1999-11-10 Diversified Pharmaceuticals, Inc. Compositions, procedes et dispositifs d'administration transdermique de medicaments
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
JP4139860B2 (ja) * 1997-11-10 2008-08-27 ストラカン インターナショナル リミティッド 浸透増強および刺激減少システム
DE19803193C1 (de) * 1998-01-28 1999-07-15 August Wolff Gmbh & Co Arzneim Pharmazeutische Zusammensetzung mit Lecithin und alpha-Bisabolol als Penetrationsbeschleuniger
AU2001282064B2 (en) * 2000-08-03 2007-02-01 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
ES2330188T3 (es) * 2001-12-07 2009-12-07 Besins Manufacturing Belgium Composicion farmaceutica en forma de gel o de solucion a base de dihidrotestoterona, su procedimiento de preparacion y sus utilizaciones.

Also Published As

Publication number Publication date
ATE356626T1 (de) 2007-04-15
US20100317631A1 (en) 2010-12-16
HUP0600234A2 (en) 2006-07-28
CA2432534A1 (fr) 2002-07-04
EP1347764B1 (fr) 2007-03-14
PT1347764E (pt) 2007-06-01
SK7932003A3 (en) 2003-11-04
DK1347764T3 (da) 2007-07-23
CZ20031761A3 (cs) 2004-01-14
HUP0600234A3 (en) 2011-04-28
WO2002051421A2 (fr) 2002-07-04
WO2002051421A3 (fr) 2002-11-07
ES2283446T3 (es) 2007-11-01
US20040044086A1 (en) 2004-03-04
CY1106595T1 (el) 2012-01-25
EP1347764A2 (fr) 2003-10-01
PL206702B1 (pl) 2010-09-30
DE50112206D1 (de) 2007-04-26
PL366101A1 (en) 2005-01-24
SI1347764T1 (sl) 2007-06-30
HRP20030510A2 (en) 2005-04-30
CA2432534C (fr) 2009-09-22
DE20121209U1 (de) 2002-06-20
EE200300305A (et) 2003-12-15

Similar Documents

Publication Publication Date Title
BR0113670A (pt) Composição farmacêutica e método para tratar hipogonadismo
DE60128673D1 (de) Verfahren zur verbesserung der grösse und des aussehens einer wunde
HUP0203652A2 (hu) GCSF-konjugátumok
EE05318B1 (et) Geelkompositsioon ja kompositsiooni transskrotaalne kasutamine hpogonadismi raviks
DK1144474T3 (da) Vandig reaktiv spartelmasse
HK1071521A1 (en) Use of a composition comprising cis-clomiphene andtrans-clomiphene in the preparation of a medicament for increasing serum levels of testosterone
BR9906477A (pt) Cicatrizante de feridas enriquecido com plaquetas aperfeiçoado
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
PT1017659E (pt) Tetra-hidronaftalenos substituidos e compostos analogos
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
AP1424A (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
HU9602740D0 (en) Halofanthine free base for the treatment of malaria and compositions
ES2166549T3 (es) Procedimiento de preparacion de 17-esteres de 9alfa,21-dihalo-pregnan-11beta,17alfadiol-20-onas.
GB9714274D0 (en) Pharmaceutical composition
BRPI0209619B8 (pt) agente promotor de crescimento capilar
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
ATE229518T1 (de) Cis-3,4-chromanderivate zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen
ATE160573T1 (de) 1,3.5 (10) - estratriene derivate mit oraler wirkung
DK1335930T3 (da) Fremgangsmåde til fremstilling af 3-oxo-4-azasteroider
BR0011261B1 (pt) composiÇço oral compreendendo perlita, e, uso de perlita.
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
AP1691A (en) A pharmaceutical composition comprising therapeutically effective quantities of calcium channel blockers in combination with quinolines.
DE60220699D1 (de) Tibolonformulierungen
SE0001631D0 (sv) New use
ATE397615T1 (de) 6-o-alkyl-2-nor-2-substituierte ketolidderivate

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20101220